Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256208 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL5407976 | 0.79 | ALDH1A1 (0.46) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL6336675 | 0.76 | ALDH1A1 (0.36) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL165885 | 0.76 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1THRBATMMAPT | |
| SCHEMBL534242 | 0.75 | CES2 (0.52) | ALDH1A1L3MBTL1THRBATMMAPT | |
| SCHEMBL7638404 | 0.75 | CES2 (0.52) | ALDH1A1L3MBTL1THRBATMMAPT | |
| SCHEMBL7636018 | 0.75 | CES2 (0.52) | ALDH1A1L3MBTL1THRBATMMAPT | |
| SCHEMBL12098093 | 0.74 | ALDH1A1 (0.43) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL380982 | 0.74 | L3MBTL1 (0.46) | ALDH1A1NPSR1TSHRL3MBTL1PPM1B | |
| SCHEMBL29998004 | 0.74 | L3MBTL1 (0.46) | ALDH1A1NPSR1TSHRL3MBTL1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| WO-2008082725-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275032-A1 | Pyridazinone compounds | HAVCR2, PLPBP, CYP3A43 | ALDH1A1 1191/4885NPSR1 3482/4885TSHR 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.